A Survey of Susoctocog Alfa (Genetical Recombination) in Participants With Acquired Haemophilia A
Recruiting
Observational Study
Acquired Hemophilia A
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Sex
- Any
- Study type
- Observational
- Participants needed
- 25 (estimated)
- Sponsor
- Takeda · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This study is a survey in Japan of Susoctocog Alfa (Genetical Recombination) intravenous injection used to treat participants with bleeding events of acquired Haemophilia A (AHA). The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study.
The main aim of the study is to check for side effec…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
\- All participants with Acquired Haemophilia A, treated with Susoctocog Alfa (Genetical Recombination).
Exclusion Criteria:
\- None
Contacts